

The Bridge to Good Health Care 1

Financial Statements for the 1st quarter of fiscal year ending March 31, 2021 (From Apr. 1, 2020 to Jun. 30, 2020)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

August 7, 2020

Highlights in Business Results



(unit: JPY million)

				Apr Jun. 2019 Results	Apr Jun. 2020 Results	Diff.	Year– over – Year		
Net sales				13,494	13,579	85	0.6%		
Operating profit			ofit	91	630	539	586.6%		
Ordinary profit			fit	187	685	498	265.9%		
Profit attributable to owners of parent				48	659	611	— %		
Basic earnings per share			per share	JPY 1.98	JPY 27.05				
1	Exchange Rate		US Dollar	JPY 109.90	JPY 107.62	Increased in sales. Increased in profit (2nd straight year).			
1 .	(average during period)		Euro	JPY 125.15	JPY 120.11				
Singapore Dollar			ingapore Dollar	JPY 80.61	JPY 76.21				
Sales	Japan	-Increased sales of Examination Gloves and Closed Drug System "NEO SHIELD" -Decreased sales of Infusion Sets			rug Mixing/Infusion	-Increased sales of Blood Bags and AV Fistula Needle			
Profit	th	-The influence of sales increase , the improved sales cost ratio and decreased selling, general and administrative expenses, resulting in increase of the operating profit and the ordinary profit -The subsidy income of extraordinary income resulted in increase of the profit attributable to owners of parent							

Summary by segment (geographical area)



(unit: JPY million)

Singapore Japan Sales incl. Sales incl. internal transaction internal transaction Sales for third party Sales for third party - Profit Profit 667 5,151 9,515 9,367 4,553 8,757 8.690 Sales Sales Increased Decreased 551 1.6% 13.1% 329 0 2,853 2,326 Profit Profit 257 278 Increased Increased 247 O 114.3% 12.4% 0 (10)Apr. - Jun. Apr. - Jun. Apr. - Jun. Apr. - Jun. 2019 2020 2019 2020

[Sales] Increased sales of Examination Gloves and Closed Drug Mixing/Infusion System "NEO SHIELD" were offset by decreased sales of Infusion Sets, reducing net sales.

[Ordinary Income]

Despite the influence of decrease sales, improved sales cost ratio and decreased selling, general and administrative expenses resulted in a profit growth.




Increased sales of Blood bags for West Asia market raised net sales.

[Ordinary Income]

The influence of sales increase resulted in a profit growth.

*This segment includes Indonesia local subsidiary.



[Sales]


Decreased sales of Infusion Sets for the Japan market due to production transfer to the plant in Philippines reduced net sales.

[Ordinary Income]

Despite the influence of decrease sales, the decrease of labor cost resulted in a profit growth.

Summary by segment (geographical area)











Apr. – Jun. 2019

Apr. – Jun. 2020



Sales change by Region (Customer's Location)






Selling, General and Admin. Expenses



(unit: JPY million)

(unit: JPY million)




	Apr Jun. 2019	Apr Jun. 2020	Diff.	Year -over- Year
Labor Cost	1,487	1,446	(41)	(2.8)%
Transport	397	434	36	9.1%
R & D	369	328	(41)	(11.2)%
Depreciation	89	84	(5)	(6.0)%
Others	1,017	853	(164)	(16.1)%
Total	3,362	3,146	(216)	(6.4)%

[Reasons for change]

Travel expenses and Clinical trial expense for the development of a new product decreased.

Ordinary profit : Compared with the previous year





Apr. - Jun. 2019

Apr. - Jun. 2020

[®]Forecast for FYE Mar. 2021



2 22 2	(unit: JPY million						
		FYE Mar. 2020 Result	FYE Mar. 2021 Forecast	Year-over-Year			
Net sales		58 <i>,</i> 569	59,500	1.6%			
Operating prof	it	2,314	2,000	(13.6)%			
Ordinary profit		2,672	2,200	(17.7)%			
Profit attributable to owners of parent	to	1,977	1,600	(19.1)%			
Basic earnings	per share	JPY 81.12	JPY 65.62				
Exchange Rate	US Dollar	JPY 108.74	JPY 108				
(average during period)	Euro	JPY 122.07	JPY 120				
	Singapore Dollar	JPY 79.28	JPY 78				



- Received the "Silver Medal of Merit" from the Japanese Red Cross Society. Jul. 2020
- Announcement of disposition of treasury shares as the stock compensation plan with transfer restrictions.
 Jul. 2020
- Treatment for refractory skin ulcer using Platelet Collection Sets "CELLAID P Type" is now covered by insurance.

Apr. 2020

Topics





The Bridge to Good Health Care 11



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.